Lepzacitinib

N/A

Report date: 2024/10/30 16:58:56
NME

Base Information

Drug NameLepzacitinib
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitorsTyrosine-protein kinase JAK3 inhibitors
TargetsTyrosine-protein kinase JAK1Tyrosine-protein kinase JAK3
Therapy Area/IndicationsDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAclaris Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPediatrix TherapeuticsAclaris Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A